The KEYNOTE-630 Trial: A Phase 3 Study of Adjuvant Pembrolizumab in High-Risk Locally Advanced (LA) Cutaneous Squamous Cell Carcinoma (cSCC)
In high-risk LA cSCC, approximately 20% of patients (pts) experience local disease recurrence within 5 years after surgical resection and adjuvant radiotherapy (RT). Therefore, improved treatment options are needed. The PD-1 inhibitors pembrolizumab (pembro) and cemiplimab have demonstrated durable antitumor activity in advanced metastatic cSCC. The randomized, double-blind, placebo-controlled, phase 3 KEYNOTE-630 (NCT03833167) trial will evaluate adjuvant pembro in pts with resectable, high-risk, LA cSCC.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: M. Schenker, M. Klochikhin, D. Kirtbaya, L. Mortier, M. Gschnell, C. Robert, N. Meyer, L. Flatz, S. Dalle, M. Beylot-Barry, T. Eigentler, R. Kloss Silverman, B. Gumuscu, J. Yuan, A. Bratland Tags: 245 Source Type: research
More News: Biology | Cancer & Oncology | Carcinoma | Physics | Radiology | Skin Cancer | Squamous Cell Carcinoma | Study